Treating iron deficiency with ferric carboxymaltose
AssigneePharmacosmos Holding A/S
InventorsTobias Sidelmann CHRISTENSEN, Philip SCHAFFALITZKY DE MUCKADELL, Lars Lykke THOMSEN, Claes Christian STROM
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.
Claims31
1-15. (canceled)
A method of treating a population of patients with iron deficiency comprising:
- (1) administering at least one dose of ferric carboxymaltose to each patient in a population of patients with iron deficiency, wherein treatment of said iron deficiency is medically indicated, and further wherein
- (a) one or more patients in the population in need of said treatment is/are at risk of low serum phosphate either prior to or during ferric carboxymaltose treatment and/or
- (b) one or more patients in the population in need of said treatment will receive at least two doses of ferric carboxymaltose within a three month period;
- (2) in each patient who is at risk for low serum phosphate, and/or in each patient who will receive a further dose of ferric carboxymaltose within said three month period, checking the patient's serum phosphate levels and, if the patient has hypophosphatemia, treating said hypophosphatemia;
- and
- (3) administering a further dose of ferric carboxymaltose to each patient in the population wherein further treatment of iron deficiency is medically indicated.
A method of treating iron deficiency with ferric carboxymaltose in a population of patients in need thereof, wherein one or more patients in the population experiences hypophosphatemia prior to a ferric carboxymaltose treatment, said method comprising the following sequential steps:
- (1) determining that each patient requires a dose of ferric carboxymaltose;
- (2) measuring each patient's serum phosphate levels before administering a dose of ferric carboxymaltose, and if the patient has hypophosphatemia, treating said hypophosphatemia;
- and
- (3) once a patient's hypophosphatemia is corrected, administering a dose of ferric carboxymaltose as medically indicated.
Dependencies are inferred from the claim text.